A comparative study of efficacy and safety in stage I hypertensive patients visiting the cardiac OPD at a tertiary care hospital

To investigate the efficacy and safety of Azilsartan 40 mg and Olmesartan 40 mg in patients with stage I systemic hypertension undergoing cardiac OPD at a tertiary care facility. A 6-month open-label comparison study was undertaken in the Department of Cardiology at Acsr Government Medical College and Hospital. All patients visiting the cardiac outpatient clinic at Acsr Government Medical College who have stage I systemic hypertension of any sex, aged 20-65, with blood pressures >140/90 mmHg, or glucose intolerance. Diagnoses for essential hypertension were made, and patients were randomised to receive either group 1 (40 mg of Azilsartan) or group 2 (40 mg of Olmesartan) after the initial screening. The individuals receiving care were instructed to come back for a fourth, eighth, twelveth, as well as twenty-fourth weeks.  Both groups showed a statistically significant drop in systolic blood pressure (P value < 0.0000001). Both medicines regulated blood pressure in similar ways. However, the Azilsartan group had a lower mean SBP and DBP than the Olmesartan group. Both medicines were well tolerated, and no severe side effects were observed throughout the research.